ubmslateNT-logo-ubm

NT Mobile Menu

Search form

Topics:

ACTRIMS 2017 Forum: MS Treatment Clinical Trials

ACTRIMS 2017 Forum: MS Treatment Clinical Trials

  • ACTRIMS 2017 Forum: MS Treatment Clinical Trials
  • Clinical Follow-up of 411 Patients with Multiple Sclerosis Ten Years after Mitoxantrone Treatment Abstract link.
  • What is the sustained effect of mitoxantrone in patients with relapsing or progressive MS?
  • Mitoxantrone offered patients a sustained (albeit reduced at 5 years) effect at 10 years; treatment was more likely to benefit less active and disabled relapsing patients.
  • NEDA Analysis by Epoch in Patients with Relapsing Multiple Sclerosis Treated with Ocrelizumab: Results from the OPERA I and OPERA II Phase III Studies Abstract link.
  • How many patients with relapsing MS had no evidence of disease activity (NEDA) on ocrelizumab vs interferon beta 1-a (IFN β-1a)?
  • Patients on ocrelizumab were much more likely to achieve NEDA than patients on IFN β-1a.
  • Evaluation of No Evidence of Progression (NEP) in Patients with Primary Progressive Multiple Sclerosis in the ORATORIO Trial Abstract link.
  • What proportion of patients with PPMS achieved no evidence of progression (NEP) on ocrelizumab?
  • Compared to placebo, ocrelizumab resulted in an increased proportion (47%) of patients with NEP at 120 weeks compared with placebo.

Presentations at the Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) Forum included a 10-year follow-up of patients after mitoxantrone treatment, a comparison of no evidence of disease activity in patients treated with ocrelizumab or IFN β-1a, and an evaluation of no evidence of progression in a trial of patients administered ocrelizumab or placebo.

Comments

I will share my anecdotal experience with you. Many years ago I treated two secondary progressive MS patients with severe myelopathies with mitoxantrone. They were both on the verge of being unable to ambulate. Over the ensuing 20 years they have been stable neurologically and remain ambulatory and independent. Although I remained well within the dosing guidelines to prevent cardiotoxicity, one of the patients has severe congestive heart failure due to mitoxantrone and is being considered a candidate for cardiac transplantation.
HWeiss, Baltimore

Howard @

I will share my anecdotal experience with you. Many years ago I treated two secondary progressive MS patients with severe myelopathies with mitoxantrone. They were both on the verge of being unable to ambulate. Over the ensuing 20 years they have been stable neurologically and remain ambulatory and independent. Although I remained well within the dosing guidelines to prevent cardiotoxicity, one of the patients has severe congestive heart failure due to mitoxantrone and is being considered a candidate for cardiac transplantation.
HWeiss, Baltimore

Howard @

Add new comment

 
Loading comments...

By clicking Accept, you agree to become a member of the UBM Medica Community.